Sepsis and inflammatory disorders - a new diagnostic opportunity

The imiwn sTLR2 RAPID test is a UKCA certified in vitro diagnostic immunochromatographic assay for the semi-quantitative measurement of human soluble Toll-like receptor 2 (sTLR2) in serum - a biomarker of inflammation and sepsis. The level of sTLR2 in serum has the potential to provide additional information to that of traditional biomarkers such as C-reactive protein (CRP).

The sTLR2 rapid test addresses a significant gap in the sepsis diagnostic market, providing scientists and clinicians with a new, potentially transformative tool, and additional opportunities for decision making and health outcomes.

Developed by a UK based innovative biotech company, with proven technology and a defined roadmap for scalability, the company is positioned for rapid growth through strategic partnerships to reach a broad market, whilst supporting research into additional diagnostic applications and platforms.

Order imiwn

Soluble Toll-like receptor 2

A soluble form of Toll-like receptor 2 (sTLR2) is present in human plasma and amniotic fluid, and shows anti-inflammatory potential. It is released early upon infection/cell activation and acts as a decoy receptor to limit inflammation. Elevated levels of sTLR2 may be present early on in patients with sepsis, and other infective and inflammatory conditions.

Find out more
imiwn sTLR2 lateral flow test cassette showing two magenta coloured lines for test and control respectively.

Results in 10 minutes

Semi-quantitative results from a 20µL serum sample in 10 minutes. The human sTLR2 rapid test kit uses proprietary sTLR2 monoclonal antibodies in a simple, convenient lateral flow format. Each kit contains 10 test devices.

Download sTLR2 Rapid Instructions for Use
Lateral flow assay development showing a close up of a dispensor for positive and negative controls.

Quality assured

Developed and manufactured in the UK according to a fully certified medical device quality assurance system (ISO13485).

UKCA Certified.

Find out more